Quantcast

Latest Regeneron Pharmaceuticals Inc. Stories

2015-04-10 12:30:28

TARRYTOWN, N.Y., April 10, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2015-03-25 12:30:39

Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., March 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2015-03-15 12:20:27

- Robust and consistent LDL-C lowering demonstrated with Praluent(TM) in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date - PARIS and TARRYTOWN, N.Y., March 15,

2015-03-15 12:20:06

Robust and consistent LDL-C lowering demonstrated with Praluent(TM) in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date TARRYTOWN, N.Y.

2015-02-26 08:33:07

TARRYTOWN, N.Y., Feb. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2015-02-18 16:27:04

In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative

2015-02-18 08:31:18

View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S. BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb.

2015-02-13 12:26:38

TARRYTOWN, N.Y., Feb. 13, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.

2015-01-26 00:20:42

TARRYTOWN, N.Y. and PARIS, Jan. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.